These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8086240)

  • 1. Effective intervention of low peak bone mass and bone modeling in the spontaneous murine model of senile osteoporosis, SAM-P/6, by Ca supplement and hormone treatment.
    Takahashi K; Tsuboyama T; Matsushita M; Kasai R; Okumura H; Yamamuro T; Okamoto Y; Kitagawa K; Takeda T
    Bone; 1994; 15(2):209-15. PubMed ID: 8086240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate.
    Khan MP; Singh AK; Singh AK; Shrivastava P; Tiwari MC; Nagar GK; Bora HK; Parameswaran V; Sanyal S; Bellare JR; Chattopadhyay N
    J Bone Miner Res; 2016 Mar; 31(3):615-29. PubMed ID: 26391310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.
    Baumann BD; Wronski TJ
    Bone; 1995 Feb; 16(2):247-53. PubMed ID: 7756054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6).
    Duque G; Macoritto M; Dion N; Ste-Marie LG; Kremer R
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E723-30. PubMed ID: 15572658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats.
    Shen V; Birchman R; Xu R; Otter M; Wu D; Lindsay R; Dempster DW
    J Clin Invest; 1995 Nov; 96(5):2331-8. PubMed ID: 7593620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol.
    Shen V; Dempster DW; Birchman R; Xu R; Lindsay R
    J Clin Invest; 1993 Jun; 91(6):2479-87. PubMed ID: 8514860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C; Woitge HW; Witte K; Lemmer B; Seibel MJ
    J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
    J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model.
    Mosekilde L; Danielsen CC; Søgaard CH; McOsker JE; Wronski TJ
    Bone; 1995 Feb; 16(2):223-30. PubMed ID: 7756051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1-34) and 17 beta-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia.
    Shen V; Dempster DW; Mellish RW; Birchman R; Horbert W; Lindsay R
    Calcif Tissue Int; 1992 Mar; 50(3):214-20. PubMed ID: 1617495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
    Li M; Mosekilde L; Søgaard CH; Thomsen JS; Wronski TJ
    Bone; 1995 Jun; 16(6):629-35. PubMed ID: 7669439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacologic therapy of osteoporosis].
    Kushida K
    Nihon Rinsho; 1994 Sep; 52(9):2367-77. PubMed ID: 7967083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss.
    Tomimori Y; Mori K; Koide M; Nakamichi Y; Ninomiya T; Udagawa N; Yasuda H
    J Bone Miner Res; 2009 Jul; 24(7):1194-205. PubMed ID: 19257825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
    Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
    J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronotherapy with active vitamin D3 in aged stroke-prone spontaneously hypertensive rats, a model of osteoporosis.
    Tsuruoka S; Nishiki K; Sugimoto K; Fujimura A
    Eur J Pharmacol; 2001 Oct; 428(2):287-93. PubMed ID: 11675047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
    Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis.
    Shiraishi A; Higashi S; Ohkawa H; Kubodera N; Hirasawa T; Ezawa I; Ikeda K; Ogata E
    Calcif Tissue Int; 1999 Oct; 65(4):311-6. PubMed ID: 10485984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of male osteoporosis with parathyroid hormone.
    Bilezikian JP; Kurland ES
    Calcif Tissue Int; 2001 Oct; 69(4):248-51. PubMed ID: 11730261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice.
    Andersson N; Lindberg MK; Ohlsson C; Andersson K; Ryberg B
    J Endocrinol; 2001 Sep; 170(3):529-37. PubMed ID: 11524233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.